Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization

Abstract

A universal vaccine containing a mixture of allogeneic cell lines, including tumor stem cells, effective against tumors regardless of type is disclosed. The cell lines are also modified to prevent interference with the immune response by any immunosuppressive agents they may secrete.

1 . A universal tumor vaccine composition that stimulates an immune response to autologous tumor cells in a patient when administered to said patient regardless of tumor type said composition comprising a mixture of two or more different allogeneic tumor cell lines
 wherein at least one of said allogeneic tumor cell lines comprises tumor stem cells, each of which tumor cell lines natively secretes an immunosuppressive agent which is TGF-β, PGE-2 or CTLA-4 and has been genetically modified to inhibit the activity or expression of said immunosuppressive agent,   wherein the cell lines in said mixture collectively express tumor associated antigens such that tumor-associated antigens representing all types of tumor is presented,   wherein said tumor type includes cancers of the colon, breast, lung, prostate, pancreas, kidney, endometrium, cervix, ovary, thyroid, or other glandular tissue carcinomas or melanoma, cancer of the central nervous system or lymphoma.   
     
     
         2 . The composition of  claim 1 , wherein said mixture comprises three or more different tumor cell lines. 
     
     
         3 . The composition of  claim 2 , wherein said mixture comprises four or more different allogeneic tumor cell lines. 
     
     
         4 . The composition of  claim 3 , wherein said mixture comprises five or more different allogeneic tumor cell lines. 
     
     
         5 . The composition of  claim 4 , wherein said mixture comprises six or more different allogeneic tumor cell lines. 
     
     
         6 . The composition of  claim 5 , wherein said mixture comprises eight or more different allogeneic tumor cell lines. 
     
     
         7 . The composition of  claim 1 , wherein said genetic modification generates intracellular antibodies. 
     
     
         8 . The composition of  claim 1 , wherein said genetic modification generates aptamers. 
     
     
         9 . The composition of  claim 1 , further comprising an allogeneic cell line genetically modified to express a cytokine. 
     
     
         10 . The composition of  claim 9 , wherein said cytokine is IL-2. 
     
     
         11 . The composition of  claim 9 , wherein said cytokine expressing allogenic cell line is a fibroblast cell line. 
     
     
         12 . A method of stimulating an immune response in a patient comprising administering to said patient the composition of  claim 1 , whereby said mixture of allogeneic tumor cells stimulates an immune response to any tumor cells in said patient,
 wherein said tumor type includes cancers of the colon, breast, lung, prostate, pancreas, kidney, endometrium, cervix, ovary, thyroid, or other glandular tissue carcinomas or melanoma, cancer of the central nervous system or lymphoma.   
     
     
         13 . The method of  claim 12 , wherein said immune response comprises a cytotoxic T lymphocyte (CTL) response. 
     
     
         14 . The method of  claim 12 , wherein said composition is administered at a dose of about 1×10 2 -1×10 10  cells. 
     
     
         15 . The method of  claim 12 , wherein said composition is administered at a dose of about 1×10 3 -1×10 7  cells. 
     
     
         16 . The method of  claim 12 , wherein said composition is administered at a dose of about 1×10 4 -1×10 6  cells.